30 December 2016 - The drug, sorafenib tosylate (Nexavar), which is used for treating advanced hepatocellular carcinoma, is not value for money, NICE has said in new draft guidance.

The committee found that sorafenib does not provide enough benefit to patients to justify its high cost, even when special considerations were applied.

However, having concluded that it could not be recommended for routine use, but recognising the unmet need for patients with this condition, the committee agreed that sorafenib tosylate should continue to be recommended for use within the Cancer Drugs Fund.

Read NICE news article